Regulatory FDA delays verdict on Beren’s rare disease drug by three months BioSpaceBeren Therapeutics is seeking approval in Neimann-Pick disease type C, an application the FDA was set to decide on by August 17.Rare DiseaseRead full story pharminent May 29, 2026 (Last updated: May 30, 2026) BioSpace Beren Therapeutics is seeking approval in Neimann-Pick disease type C, an application the FDA was set to decide on by August 17. Rare Disease Read full story Post navigation Previous: Pfizer bets up to $10.5B in 12-candidate cancer collab with China’s InnoventNext: Replimune gives cancer immunotherapy a third try after FDA leadership shakeup Related Stories Regulatory Ultragenyx wins FDA approval for first treatment targeting root cause of GSDIa pharminent August 20, 2026 Regulatory Regeneron wins FDA approval to challenge Ipsen for rare bone disease market pharminent August 20, 2026 Regulatory FDA grants accelerated approval to Ultragenyx’s Genglycos gene therapy pharminent August 20, 2026
